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Background: Although a number of medicines are available for the management of hypertension, the organ
damage induced by hypertension is not resolved. The aim of this study was to investigate the protection of
ginsenoside Rg1 (Rg1) against vascular remodeling and organ damage in spontaneously hypertensive rats (SHR).
Methods: Male SHR were treated with 5, 10 or 20 mg/kg Rg1 through intraperitoneal injection per day for
1 month. SHR or Wistar-Kyoto rats (WKY) receiving vehicle (saline) was used as control. Blood pressure detection
and pathological stain, transmission electron microscope, immunohistochemical assay were used to elucidate the
protection of Rg1.
Results: Blood pressures were not different between control SHR rats and Rg1 treated SHR rats, but Rg1 improved
the aortic outward remodeling by lowering the lumen diameter and reducing the media thickness according the
histopathological and ultrastructural detections. Rg1 also protected the retinal vessels against inward remodeling
detected by immunohistochemical assay. Furthermore, Rg1 attenuated the target heart and kidney damage with
improvement on cardiac and glomerular structure.
Conclusions: These results suggested that Rg1 held beneficial effects on vascular structure and further protected
against the organ-damage induced by hypertension. These findings also paved a novel and promising approach to
the treatment of hypertensive complications.
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Recent evidence suggests that the average blood pressure
(BP) in children and adults is rising in the last two dec-
ades [1]. Hypertension is becoming one of the main risk
factor for cardiovascular and renal vascular disease, and
also for mortality around the world [2]. Although the
blockers of calcium channel and inhibitors of rennin-
angiotensin system are widely applied for clinical ther-
apy, the target-organ damage accompanied by hyperten-
sion is still not solved. Therefore, new therapeutic* Correspondence: jiangbh@mail.shcnc.ac.cn; daguo@mail.shcnc.ac.cn
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reproduction in any medium, provided the orstrategies and new medicines to attenuate hypertension-
complications are urgently needed [3].
Panax notoginseng, one of the most frequently used
traditional Chinese medicine, is well known for its effi-
cacy in promoting blood circulation, ameliorating patho-
logical hemostasis, alleviating pain [4-7]. The main
active components of Panax notoginseng include more
than 30 different types of saponins, among which
Rg1and Rb1 are found in the highest content. A number
of clinical and physiological effects of Rg1 have been
described recently, such as inhibition of tubular epithelial
to myofibroblast transition [8], improvement of myocardial
dysfunction in rats with burn injuries [9], amelioration of
hepatic microcirculatory disturbances [10], anti-
hyperglycemic activity [11], and improvement oftd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Chemical structure of Rg1.
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tified to be an angiogenic factor, which can induce neovas-
cularizaton in vivo and promote proliferation and
tubulogenesis of endothelial cells in vitro [13-15]. Further
mechanism research revealed that Rg1 could activate
phosphatidylinositol-3 kinase Akt pathway, inhibit P38
MARK pathway [16]. Recent studies have demonstrated
the beneficial effects of Rg1 on improvement of cardial and
renal function [17].
Thus, we carried out the present study in SHR rats
to test our hypothesis that Rg1 may inhibit the vascu-
lar remodeling and targeted-organ damage induced by
hypertension.
Methods
Animals and Rg1 treatment
2 month old male Wistar-Kyoto rats (WKY, 280–300 g)
and spontaneous hypertension rats (SHR, 280–300 g)
were purchased from Shanghai Center of Experimental
Animals, Chinese Academy of Sciences. Rats were accli-
matized in temperature and humidity-controlled rooms
with a 12-h dark/light cycle throughout the study. After
8 week high salt diet, WKY rats that treated by saline
were used as normal control (WKY, n = 10). SHR rats
were randomly divided into four groups (10 per group):
rats that treated by saline were used as hypertension
model (SHR); rats in the other three groups were treated
by 5 mg/kg Rg1 (SHR-Rg1(5)), 10 mg/kg Rg1 (SHR-Rg1
(10)) or 20 mg/kg Rg1 (SHR-Rg1(20)). Saline or Rg 1
(dissolved in saline) were given once a day intraperitone-
ally. The purity of Rg1 that purchased from Shanghai
Yousi Bio-Tech Co., Ltd. was more than 99% evaluated
by high-performance liquid chromatography (Additional
file 1: Figure S1) and the chemical structure of Rg1 was
elucidated by 13 C NMR (Additional file 2: Figure S2,
Additional file 3: Figure S3), which is in agreement with
those previous report [18]. 8.0% high salt diet was fed
during the whole research, and saline or Rg1 was given
from the ninth week of experiment for 4 weeks. The
whole experiment protocol was shown in Additional file
4: Figure S4. Experimental procedures were approved by
the institute animal ethics committee (SIMM-AE-GDA-
2010-05) and were in accordance with the National
Institute of Health guidelines.
Measurement of blood pressure in conscious rats
Systolic blood pressure (SBP) and diastolic pressure (DBP)
were measured 0.5 h after the administration of Rg1 at the
indicated time (Additional file 4: Figure S4) using the tail-
cuff method. Briefly, the rats were placed in a restrainer
with heating pad. The blood pressure was continuously
recorded by a tail-cuff apparatus (ALC-NIBP, Shanghai
Alcott Biotech Co., China) that was controlled with a com-
puter after stabilizing at 37°C for at least 10 min.Measurements of hemodynamic parameters
The rats were anesthetized, and a Mikro-tipped SPR-320
catheter (Millar Instruments Inc) was inserted through
the right carotid artery into left ventricle. Heart rate,
mean arterial pressure (MAP), left ventricular systolic
pressure (LVSP), end-diastolic pressure (EDP) of rats
were recorded by PowerLab 8/30 instrument (ADInstru-
ments, Australia). Maximal rate of pressure development
for contraction (+dP/dtmax) and maximal rate of pres-
sure development for relaxation (−dP/dtmax) were all cal-
culated from the continuously collected pressure signal.
Histopathological detection
After the treatment of Rg1, ascending aorta, heart and
kidney of each rat were weighed, and then fixed by 4%
neutral-buffered paraformaldehyde for 24 h. Heart index
was calculated as that the heart weight was divided by
body weight. All the specimens were paraffin-embedded,
cut at 5 μm and were stained with haematoxylin and
eosin. Photomicrographs were taken using an Olympus
BX51 microscope plus Olympus DP71 CCD camera
(Olympus Corporation, Japan). Software Image-Pro Plus
version 6.0 was used to detect lumen diameter and
media thickness of aorta. The aortic lumen diameter was
calculated as the mean of the inner diameters through
the center of vascular circle, and the media thickness
defined as the distance between the internal and exter-
nal elastic lamina. At least 16 values were measured
from the points distributed evenly on every aorta.
Paraffin-embedded slices were also stained with 0.1%
picric sirius red (Sigma-Aldrich Inc, St Louis, USA) for
fibrosis detection.
Immunohistochemical detection on retinal vessels
Rat eyes were fixed in 4% neutral-buffered paraformalde-
hyde and the solution was replaced every two days. Be-
fore retinal dissection, the eyes were washed by running
water for 20 mins. Retinas were dissected, flattened on
slides, washed by PBS, then incubated in PBS containing
0.5% Triton X-100 and 10% normal goat serum for 1 h
Table 1 Effects of Rg1 on blood pressure
WKY SHR SHR-Rg1(5) SHR-Rg1(10) SHR-Rg1(20)
SBP(mmHg) 133.7 ± 2.2 184.5 ± 3.4### 186.0 ± 2.4### 183.5 ± 3.3### 183.0 ± 4.2###
DBP(mmHg) 97.5 ± 2.0 139.0 ± 3.0### 138.0 ± 2.4### 139.1 ± 2.8### 133.8 ± 3.9###
HR (bpm) 360.6 ± 14.0 393.6 ± 12.5# 366.7 ± 13.7 412.6 ± 8.9 433.5 ± 9.3*
MAP(mmHg) 111.5 ± 6.3 170.1 ± 16.7### 181.6 ± 14.0### 175.4 ± 37.4### 193.7 ± 10.4###
EDP(mmHg) 6.1 ± 1.7 7.5 ± 3.0 3.1 ± 1.0 4.8 ± 3.9 5.5 ± 1.8
LVSP(mmHg) 120.9 ± 7.1 207.1 ± 17.9### 213.7 ± 21.1### 224.3 ± 35.4### 217.5 ± 16.8###
+dP/dtmax (mm HgS
-1) 8661.1 ± 717.7 11735.7 ± 635.8## 13063.6 ± 470.8### 12651.9 ± 803.0## 12636.7 ± 514.7###
-dP/dtmax (mm HgS
-1) −7514.6 ± 626.0 −11272.1 ± 872.8## −12410.0 ± 595.7### −11330.2 ± 722.8### −11464.1 ± 534.8###
HW/BW(mg/g) 2.9 ± 0.2 3.9 ± 0.05# 3.8 ± 0.08# 3.8 ± 0.07# 3.6 ± 0.06# **
All the values are expressed as mean ± S.E. Systolic pressure (SBP), diastolic pressure (DBP), heart rate (HR), mean arterial pressure (MAP), maximum rate of
pressure development for relaxation (−dP/dtmax), maximum rate of pressure development for contraction (+dP/dtmax), left ventricular systolic pressure (LVSP) were
demonstrated. Heart weight divided by body weight (HW/BW) is also calculated. MAP, EDP, LVSP, +dp/dtmax, -dp/dtmax were acquired using Millar catheter and
recorded by PowerLab 8/30 instrument (ADInstruments, Australia). Heart rate, SBP and DBP were acquired by tail-cuff apparatus. Mean values of data from
different treatment groups were compared using one-way ANOVA. After confirming the equal variances, unpaired Student’s t-test was used to compare difference
between means of two groups using SigmaPlot software. #P< 0.05, ###P< 0.001 versus WKY; **P< 0.01, ***P< 0.001 versus SHR. n = 10 for each group.
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inas were incubated with the α-SMA-Cy3 (Sigma-
Aldrich, Germany) and lectin-FITC (Sigma-Aldrich,Figure 2 Effects of Rg1 on aorta structure. (A) Representative sections o
Representative sections of the aortas staining with hematoxylin-eosin (mag
Sirius red ((magnification 40X) (D) Representative sections of the aortas sta
lumen diameter. (F) Quantitative data of media thickness. ###p< 0.001 com
group.Germany) at 1000 times dilution at 37°C for 1 h. Ret-
inal artery could be stained by both α-SMA-Cy3 and
lectin-FITC positively. Photomicrographs were takenf the aortas staining with hematoxylin-eosin (magnification 40X). (B)
nification 200X) (C) Representative sections of the aortas staining with
ining with Sirius red (magnification 200X) (E) Quantitative data of
pared with WKY, ***p< 0.001 compared with SHR. n = 4 for each
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inal vessel diameter was directly measured at the point
of 0.5 mm from the middle of the arteriole.Transmission electron microscopy
Aorta, heart, kidney samples were dissected, cut into
small pieces and fixed with 2.5% glutaraldehyde in 0.1 M
sodium cacodylate buffer for 2 h in 4°C. The specimens
were then rinsed, post-fixed in cacodylate -buffered 2%
osmium tetroxide, and embedded as monolayers in LX-
112 (Ladd Research Industries, USA). Ultrathin sections
were contrasted with uranyl acetate followed by lead citrate
and observed with a Tecnai 12 BioTwin transmission elec-
tron microscope (Philips Electronic Instruments, USA).
Random sections were selected for analysis by an electron
microscopy technician blinded to the treatments.Data analysis
All quantitative values are given as mean± S.E. Mean
values of data from different treatment groups were
compared using one-way ANOVA. After confirming the
equal variances, unpaired Student’s t-test was used to
compare difference between means of two groups usingFigure 3 Effects of Rg1 on retinal remodeling induced by hypertensio
lectin (green) and α-SMA antibody (red). (A) lectin positive arteries. (B) α-SM
Quantitative data of lumen diameter for retinal arteries. ###p< 0.001 comp
group.SigmaPlot software. P < 0.05 was considered to be statis-
tically significant.Results
No influence of Rg1 on blood pressure
The structure of Rg1 was shown in Figure 1. Hyperten-
sion is well established as a stimulus for cardiovascular
remodeling. It was therefore important to determine
whether Rg1 regulated blood pressure or not. Through-
out the experiments, the blood pressure in the four SHR
groups were significantly higher than in the WKY group,
but no regulation was found for Rg1 on blood pres-
sure during the whole experiment using tail-cuff
method. Furthermore, Rg1 did not show considerable
regulation on left ventricular function demonstrated
by HR, MAP, +dP/dtmax, -dP/dtmax and LVSP
detected by Millar catheter (Table 1).Rg1 reduces aortic remodeling
Aortic structure was investigated by histopathological
analysis using haematoxylin and eosin stain and shown
in Figure 2A and Figure 2B. The cell alignment was un-
regular and cell density was reduced in SHR relative to
WKY, and Rg1 treatment markedly attenuated thisn. Whole-mount double-staining of retinal vessels with FITC-coupled
A–positive arteries. (C) The merged picture for both (A) and (B). (D)
ared with WKY; **p< 0.01, **p< 0.01 compared with SHR. n = 4 for each
Figure 4 Representative photographs of transmission electron
microscopy for vascular smooth muscle cells. Arrows indicate
mitochondria. n = 3 for each group. The representative figures were
shown.
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vascular contractility was detected by picro sirus stain.
No significant improvement of Rg1 on vascular fibrosis
was found (Figure 2C, D). It is well known that long
term hypertension could induce vascular remodeling in-
cluding greater values of lumen diameter and media
thickness. The lumen diameter was 1.86 ± 0.02 mm in
SHR rats compared with 1.49± 0.02 mm in WKY rats
(P<0.001). Rg1 decreased this outward remodeling signifi-
cantly (P<0.001 for 5 mg/kg Rg1; P<0.05 for 20 mg/kg
Rg1; Figure 2E). Furthermore, the thickening of aortic
media was clearly observed in the arteries of SHR compar-
ing with WKY (173.7± 4.3 μm versus 100.0± 1.7 μm;
P<0.001), and the media thickness in 5 mg/kg Rg1 treated
SHR decreased to 156.6± 2.1 μm (P<0.01; Figure 2F).Figure 5 Rg1 improved heart and kidney structure of SHR detected b
from heart tissue of WKY, SHR, SHR-Rg1(5), SHR-Rg1(10), SHR-Rg1(20) with 2
tissue of WKY, SHR, SHR-Rg1(5), SHR-Rg1(10), SHR-Rg1(20) with 200 X magnRg1 reduces retinal vascular remodeling
Hypertension is a strong stimulus not only on conduct-
ance vessel such as aorta, but also on resistance vessel
such as retinal arteries [19]. In the present study, we
investigated effects of Rg1 on the remodeling of small
retinal arteries (Figure 3). Arteries and veins were distin-
guished by double-staining of the retinal blood vessels
with lectin-FITC and an anti-α-SMA-Cy3 antibody,
which resulted in a more pronounced α-SMA stain-
ing of small arteries and arterioles. The remodeling
of retinal arteries was evaluated by arteries diameter
at the point 0.5 mm to the middle of the arteriole.
Hypertension induced considerable decrease on ret-
inal arterial diameter in SHR (57.06 ± 3.47 μm) com-
pared with WKY (104.65 ± 5.695 μm; P < 0.001).
While Rg1 inhibited this inward remodeling induced by
hypertension, the diameter values were 72.2 ± 4.2 μm
(SHR-Rg1(5)), 61.5 ± 3.9 μm (SHR-Rg1(10)) and
69.8 ± 5.0 μm (SHR-Rg1(20)), respectively.
Rg1 protects the ultra-structural integrity of aorta
The ultra-structure of aorta was examined using trans-
mission electron microscopy (Figure 4). Vascular smooth
muscle cell is the main cell type of aorta and play im-
portant role on vascular function. In the present study,
we detected the mitochondrial ultra-structure of smooth
muscle cells of aorta. The mitochondria of SHR showed
irregularly and spherical shaped, especially swollen with
electron-lucent matrix. With Rg1 treatment, although
the matrix of mitochondria was partial disruption, but
no-swollen cristae was detected.
Rg1 protects against the impairment of hypertensive
heart and kidney
Cardial and renal deterioration are both complications
in patients with hypertension. Histopathological detec-
tion was performed in order to investigate the protective
effects of Rg1 on structure of heart and kidney in SHR.y hematoxylin-eosin stain. (A) Representative photomicrographs
00 X magnification. (B) Representative photomicrographs from kidney
ification. n = 4 for each group.
Figure 6 Rg1 decreased heart fibrosis induced by hypertension. (A) Representative perivascular area of whole heart stained by Sirius red. (B)
Representative few-vascular area of whole heart stained by Sirius red. The position of collagen deposition was stained in red. n = 4 for each
group.
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tic in SHR compared with WKY, and this impairment
was attenuated in SHR-Rg1 groups (Figure 5A). This
finding is consistence with the result of heart index, the
values were 2.9±0.2 mg/kg (WKY), 3.9± 0.05 mg/kg
(SHR), 3.8±0.08 mg/kg (SHR-Rg1(5)), 3.8 ± 0.07 mg/kg
(SHR-Rg1(10)), 3.6 ± 0.06 mg/kg (SHR-Rg1(20)), re-
spectively (Table 1). The typical photomicrographs of
glomeruli were shown in Figure 5B. Glomeruli of
SHR showed prominent hyalinization (mesangial
thickening) comparing with WKY rats. SHR treated
with Rg1 showed the reduction in the development
of hyalinization.Rg1 protects against cardio-fibrosis induced by
hypertension
Myocardial fibrosis, the common end point of hyperten-
sive heart disease, has been linked to the development of
contractile dysfunction and cardiac failure. Picro sirus
stain showed the fibrotic area was larger in SHR com-
pared with WKY at the perivascular area. With Rg1
treatment, the fibrotic areas were considerably smaller
than SHR (Figure 6A). Thicker and darker stain of colla-
gen fiber was seen on SHR compared with WKY at the
few-vascular area; while collagen fiber became thinner,Figure 7 Rg1 improved ultra-structure of heart and kidney. (A) Electro
micrograph of glomerular basement membrane. n = 3 for each group. Theweaker and more discontinuous with Rg1 treatment
(Figure 6B). No significant improvement of Rg1 on renal
fibrosis was detected (data not shown).
Rg1 protects the ultra-structure integrity of heart and
kidney of SHR
The damage on mitochondria of cardiomyocyte included
swelling, disorganization or even disappearance of cris-
tae in SHR group. While, no overt ultra-structural ab-
normality was observed in ventricular samples from Rg1
treated groups, with relative organized mitochondria
(Figure 7A). Electron microscopy also demonstrated a
heterogeneous thickening of the glomerular basement
membrane, accompanying irregular arrangement or inter-
adhesion of the podocytes in SHR group. With Rg1 treat-
ment, podocytes were in very regular array (Figure 7B).
Discussion
This study assessed the protective effects of Rg1 on
hypertension target-organ damage in SHRs. The main
findings are as follows: (i) Rg1 attenuated the outward
remodeling of aorta. (ii) Rg1 decreased the inward re-
modeling of small artery. (iii) Rg1 improved the cardial
hypertrophy and fibrosis. (iv) Rg1 maintained the normal
structure of kidney.n micrograph of mitochondria marked by arrow in heart. (B) Electron
representative figures were shown.
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take causes adverse structural and functional effects in
the cardiovascular system [20,21]. Excessive salt intake is
often associated with an increase in arterial pressure
and, consequently, increases in arterial pressure may
partially mediate salt-related adverse effects [22]. In
addition to the well-admitted effect of sodium on blood
pressure, several clinical and experimental observations
are in favour of non-pressure-related effects of salt that
could contribute to its influence on cardiovascular out-
come [23]. High salt intake caused hypertrophic re-
sponse, then concentric cardiac-remodeling [24]. High
dietary salt led to widespread fibrosis and increased
TGF-β1 in the heart and kidney in normotensive and
hypertensive rats, suggesting that excessive salt intake
may be an important direct pathogenic factor for cardio-
vascular disease [21].
Up to now, cardiovascular disease is still the most im-
portant factor that affects people’s life, especially the
hypertension [1,2,25]. To delay or prevent hypertension
target-organ, containing heart failure and renal failure, is
essential to improve patient’s quality of life [26]. In
agreement with previous reports that the most com-
mon change found in large arteries in hypertension
is an “outward hypertrophic remodeling”, we detected
the increased lumen diameter and wall thickness in
SHR compared with WKY. In hypertensive large ar-
teries, these changes appear to be the consequence
of cellular hypertrophy, cell hyperplasia, increased
deposition of fibrillar or nonfibrillar matrix, or from
a combination of these events [27-30]. Remodeling of
the small resistance arteries may involve an inward
or an outward remodeling [19,31]. In the present
study, we confirmed an inward remodeling in small
retinal arteries of SHR compared with WKY. Rg1
treatment not only reduced the outward remodeling
of large conductance arteries but also attenuated the
inward remodeling of small resistance arteries, al-
though no regulation of Rg1 on blood pressure was
found. These results agree with those of other
reports that ACE inhibitors are effective in control-
ling or reversing vascular remodeling, not depending
on the anti-hypertensive effects [32,33].
The final goal of novel therapy of hypertension is not
only to normalize the blood pressure level but also to
prevent end-organ damage, such as cardiac hypertrophy
and renal dysfunction [26,34]. Altered retinal arteries
diameter has also been demonstrated to be associated
with heart failure, suggesting that evaluation of the ret-
inal microvasculature may be a useful predictor of target
organ damage [35,36]. Collagen deposition is the risk
factor which plays an important role in development of
organ failure, such as heart failure and renal failure [37].
The myocardial matrix becomes less distensible, as theformation of the adducts in collagen resists normal turn-
over. Therefore, monitoring cardiac fibrosis and use of
medicines that reverse collagen accumulation might rep-
resent a novel opportunity to alter the natural history of
hypertensive heart disease.
In the previous report, the presence of myocardial
hypertrophy and fibrosis in SHR was obvious at early
stage, but the diastolic and systolic dysfunction did not
occur until 13 to 18 months of age of SHR [38]. This find-
ing is in consistence with our present study. It is hopeful
that the improvement of Rg1 on cardiac function could be
detected by elongation of Rg1 treatment or selection of
SHR more than 13 month old, basing on the anti-fibrotic
effects of Rg1 at the early stage of hypertension.
We detected heart rate on conscious SHR during the
experiment using tail-cuff apparatus, and up-regulation
of Rg1 on heart rate was found. Increase of heart rate
induced by Rg1 should be considered as a side effect in
cardiovascular disease. Shen et al. have reported that
Rg1 down-regulated heart rate in anesthetized mice trea-
ted by glutamate [39]. The difference between our report
and Shen et al. maybe derive from the different species
used, suggesting the increase of Rg1 on heart rate may
not occur if animal model other than SHR was used.
Different biological response induced by extract from
herbs between species was also reported [40,41]. Further
study was necessary to clarify the effects of Rg1 on heart
rate on different species and the underlying mechanism.Conclusion
In summary, Rg1 performed cardiac and renal protec-
tion with inhibition of vascular remodeling not only on
large conductance artery but also on small resistance
artery. The unique structure and efficiency of Rg1 af-
ford a great deal of potential for further optimization
of this natural compound into therapeutics for hyper-
tension related abnormalities.Additional files
Additional file 1: Figure S1. The representative chromatogram of high-
performance liquid chromatography for Rg1. Agilent 1100 HPLC system
was used and the detection wavelength was set at 280 nm. The mobile
phase consisted of (A) acetonitrile and (B) 0.05% aqueous trifluoroacetic
acid (V/V), using a gradient elution of 2%-10% A at 0–7 min, 10%–30% A
at 7–20 min, 23%–27% A at 20–35 min, and 27%–60% A at 35–50 min .
Additional file 2: Figure S2. 13C NMR spectrum of Rg1 detected by
Bruker AM-400 spectrometer.
Additional file 3: Figure S3. Structure elucidation of Rg1. (A) Chemical
structure of Rg1. (B) 13C NMR (100 MHz) spectral data for Rg1.
Additional file 4: Figure S4. Experimental protocol. Rg1 treatment was
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